|
MX358660B
(en)
*
|
2012-01-12 |
2018-08-30 |
Univ Yale |
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase.
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN106456699B
(en)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
Compositions and methods for inhibiting anti-apoptotic Bcl-2 proteins as anti-aging agents
|
|
CA2955972A1
(en)
|
2014-07-22 |
2016-01-28 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
US10071164B2
(en)
*
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
KR102110566B1
(en)
|
2015-01-20 |
2020-05-13 |
아비나스 오퍼레이션스, 인코포레이티드 |
Compounds and methods for targeted degradation of androgen receptors
|
|
GB201504314D0
(en)
*
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
WO2016149668A1
(en)
|
2015-03-18 |
2016-09-22 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
JP2018531983A
(en)
|
2015-11-02 |
2018-11-01 |
イエール ユニバーシティ |
Proteolysis-inducing chimera compound and its preparation and use
|
|
EP3445452A4
(en)
|
2016-04-21 |
2019-10-30 |
BioVentures, LLC |
Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
|
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
|
EP3500299B1
(en)
|
2016-08-19 |
2023-12-13 |
BeiGene Switzerland GmbH |
Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
|
|
US20180072711A1
(en)
*
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
JP6899993B2
(en)
*
|
2016-10-04 |
2021-07-07 |
国立医薬品食品衛生研究所長 |
Heterocyclic compound
|
|
HUE061847T2
(en)
|
2016-10-11 |
2023-08-28 |
Arvinas Operations Inc |
Compounds and methods for the targeted degradation of androgen receptor
|
|
CA3209295A1
(en)
|
2016-11-01 |
2018-06-07 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
|
PL3689868T3
(en)
|
2016-12-01 |
2024-03-11 |
Arvinas Operations, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CA3047586A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10723717B2
(en)
|
2016-12-23 |
2020-07-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzthiophene compounds, compositions comprisng them and their use in treatment
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
CN111801334B
(en)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors
|
|
CN109912655B
(en)
*
|
2017-12-13 |
2021-12-10 |
上海科技大学 |
ALK protein degradation agent and anti-tumor application thereof
|
|
US10519152B2
(en)
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
CN112105360B
(en)
|
2018-01-22 |
2024-01-30 |
生物风险投资有限责任公司 |
BCL-2 protein degrading agent for cancer treatment
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
KR20210006356A
(en)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
Proteolysis modulators and related methods of use
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
US11667621B2
(en)
|
2018-06-11 |
2023-06-06 |
Stevens Institute Of Technology |
Antiestrogen compounds
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
EP3831811A4
(en)
|
2018-07-31 |
2022-04-20 |
Fimecs, Inc. |
Heterocyclic compound
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
JP2022516401A
(en)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス， インコーポレイテッド |
IRAK Degradants and Their Use
|
|
US20220160890A1
(en)
|
2019-02-21 |
2022-05-26 |
Locki Therapeutics Limited |
Survival-targeting chimeric (surtac) molecules
|
|
KR20220006139A
(en)
|
2019-04-05 |
2022-01-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
STAT degradation agents and uses thereof
|
|
AU2020274113A1
(en)
|
2019-05-14 |
2021-11-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3989966A4
(en)
|
2019-06-28 |
2023-09-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP7548992B2
(en)
|
2019-07-17 |
2024-09-10 |
アルビナス・オペレーションズ・インコーポレイテッド |
Tau Protein Targeting Compounds and Related Methods of Use - Patent application
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
TW202136240A
(en)
|
2019-12-19 |
2021-10-01 |
美商亞文納營運公司 |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
JP2023518423A
(en)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス， インコーポレイテッド |
MDM2 degrading agents and their uses
|
|
WO2021231174A1
(en)
|
2020-05-09 |
2021-11-18 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
|
TW202210483A
(en)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Crystalline forms of irak degraders
|
|
CN112094307A
(en)
*
|
2020-09-28 |
2020-12-18 |
深圳市术理科技有限公司 |
Compound for target ubiquitination degradation of ER alpha protein and application thereof
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
CA3214408A1
(en)
|
2021-03-23 |
2022-09-29 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20230171979A
(en)
|
2021-04-16 |
2023-12-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
Modulators of BCL6 protein degradation and related methods of use
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
BR112023023223A2
(en)
|
2021-05-07 |
2024-01-30 |
Kymera Therapeutics Inc |
CDK2 DEGRADERS AND USES THEREOF
|
|
CN115728275A
(en)
*
|
2021-09-01 |
2023-03-03 |
中国人民解放军疾病预防控制中心 |
Chemical endocrine disrupting activity assessment method based on high content imaging technology
|
|
IL312330A
(en)
|
2021-10-25 |
2024-06-01 |
Kymera Therapeutics Inc |
Tyk2 degraders and uses thereof
|
|
TW202339738A
(en)
|
2022-01-31 |
2023-10-16 |
美商凱麥拉醫療公司 |
Irak degraders and uses thereof
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|